United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be avail.

United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023

BeiGene

BioMarin Pharmaceutical

Incyte

argenx

Legend Biotech

Bio-Techne

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).

7 Biotech Stocks That Could Cure Your Portfolio Woes

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 43rd Annual Meeting and Scientific Sessions in Denver, Colorado on April 19-22, 2023, and at the American Thoracic Society (ATS) International Conference in Washington, D.C. on May 19-24, 2023.

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings

Alnylam Pharmaceuticals

Apellis Pharma

Ascendis Pharma

Amicus Therapeutics

Horizon Pharma

Madrigal Pharmaceuticals

Sarepta Therapeutics

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

These Are the Top 10 Holdings of Avoro Capital Advisors

AbbVie

Crocs

CVS Health

UnitedHealth Group

Williams

With the goal of generating strong risk-adjusted returns and capital appreciation, Bernard Horn (Trades, Portfolio)'s Polaris Capital Management invests in discounted but high-quality stocks in developed as well as emerging markets.

A Look at Bernard Horn's Top Holdings Ahead of Value Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company's business during a fireside chat session at the Oppenheimer 33rd Annual Healthcare Conference. The session will take place on Monday, March 13, 2023, from 11:20 a.m. to 11:50 a.m.

United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company's business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston. The session will take place on Tuesday, March 7, 2023, from 9:10 a.m. to 9:40 a.m.

United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates

United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Senior Vice President of Product Development Pat Poisson - Executive Vice President of Technical Operations Conference Call Participants Jessica Fye - JPMorgan Justin Phillips - Morgan Stanley Hartaj Singh - Oppenheimer & Co. Ashwani Verma - UBS Joseph Thome - Cowen and Company Andreas Argyrides - Wedbush Securities Operator Good morning and welcome to the United Therapeutics Corporation Fourth Quarter and Full Year 2022 Earnings Webcast. My name is Devin, and I will be your conference operator today.

United Therapeutics Corporation (UTHR) Q4 2022 Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company's treprostinil-based therapies reached an all-time high during the fourth quarter of 2022.

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results

United Therapeutics (UTHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy United Therapeutics (UTHR) Ahead of Earnings?

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2022 financial results before the market opens on Wednesday, February 22, 2023. United Therapeutics will host a public webcast Wednesday, February 22, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations.

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023

The market has swiftly priced in United Therapeutics Corporation's patent dispute. The company exhibits strong profitability momentum, with growth coming in at a low cost to earnings.

United Therapeutics: Incremental Profitability Gains Justify Premium

Zoetis

UTHR vs. ZTS: Which Stock Is the Better Value Option?

United Therapeutics (UTHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)

UTHR vs. ESALY: Which Stock Is the Better Value Option?

UTHR or ESALY: Which Is the Better Value Stock Right Now?

Genmab - ADR

Vertex Pharmaceuticals

Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof.

3 Biotech Companies to Watch in 2023

Casey's General Stores

UTHR and AXON made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2023.

Best Momentum Stock to Buy for January 4th

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company's business during a fireside chat session at the 41st annual J.P. Morgan Healthcare Conference in San Francisco.

United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference

Immunocore Holdings

Intra-Cellular Therapies

Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

3 Drug Stocks Most Wall Street Analysts Are Bullish About

GlaxoSmithKline

Sanofi

United Continental Hlds

Ulta Beauty

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.

5 Momentum Stock Bargains Hunters Would Love Chasing

ChampionX

Enphase Energy

LPL Financial Hlds

Shockwave Medical

we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.

Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left

Corcept Therapeutics

Novo Nordisk

Regeneron Pharmaceuticals

If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed.

News for United Therapeutics Stock (UTHR)